Trial Profile

Phase II Study of Inotuzumab Ozogamicin in Patients With B-Cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inotuzumab ozogamicin (Primary)
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Therapeutic Use

Most Recent Events

06 Feb 2025 Planned primary completion date changed from 28 Feb 2025 to 28 Feb 2027.
06 Feb 2025 Planned End Date changed from 28 Feb 2025 to 28 Feb 2027.
25 Oct 2023 Results (n=26) assessing safety and efficacy of Inotuzumab Ozogamicin for Measurable Residual Disease in Acute Lymphoblastic Leukemia published in the Blood

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com